<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990951</url>
  </required_header>
  <id_info>
    <org_study_id>MJ 3001-09</org_study_id>
    <nct_id>NCT00990951</nct_id>
  </id_info>
  <brief_title>Study of Efficacy of Association of Senna Alexandrina Mill and Associations on Functional Intestinal Constipation</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Study of Efficacy of Association of Senna Alexandrina, Cassia Fistula, Tamarindus Indica, Coriandrum Sativum, Periandra Mediterranea in Patients With Functional Intestinal Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marjan Industria e Comercio ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marjan Industria e Comercio ltda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of association of Senna alexandrina&#xD;
      Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra&#xD;
      mediterranea Taub. in patients with functional constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III trial, placebo-controlled with a parallel-group design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The study was interrupted by recruitment failure.&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average frequency of bowel movements measured at baseline and at 2 weeks of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of consecutive days that patients do not evacuate</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of stools with pain and difficulty</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degree of improvement of constipation according to the subjective evaluation of the volunteer, measured by the scores of the Global Assessment of the patient</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Senna alexandrina and associations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Senna alexandrina and associations</intervention_name>
    <description>Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub&#xD;
1 tablet PO twice a day</description>
    <arm_group_label>Senna alexandrina and associations</arm_group_label>
    <other_name>Brand name: Tamaril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18-65 years with functional constipation by ROME IIII criteria&#xD;
&#xD;
          -  In the opinion of the investigator the patient will adhere to the protocol&#xD;
&#xD;
          -  Voluntary able to understand the nature and purpose of the study, including the risks&#xD;
             and adverse effects and with intent to cooperate with the researcher and act in&#xD;
             accordance with the requirements of the entire protocol, which was confirmed by&#xD;
             signing the Consent Informed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensitivity to any component&#xD;
&#xD;
          -  pregnant or lactating&#xD;
&#xD;
          -  abdominal pain of unknown etiology&#xD;
&#xD;
          -  suspected intestinal occlusion and sub-occlusion&#xD;
&#xD;
          -  suspected abdominal inflammatory conditions (as appendicitis, peritonitis, cystitis,&#xD;
             endometritis)&#xD;
&#xD;
          -  Crohn disease and colitis&#xD;
&#xD;
          -  Suspected intestinal constipation due abdominal surgery, neurological disorders (as&#xD;
             aganglionoses, Parkinson disease, medullar tumor, stroke, multiple sclerosis),&#xD;
             systemic sclerosis, multiple myeloma, scleroderma&#xD;
&#xD;
          -  Subjects with congenital mega colon, anorectal congenital malformation, inflammatory&#xD;
             bowel disease or intestinal carcinoma&#xD;
&#xD;
          -  history of mal-absorption diseases&#xD;
&#xD;
          -  history of anemia, weight loss or anal bleeding&#xD;
&#xD;
          -  history of hypothyroidism, hyperthyroidism and insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  known of positive result for human immunodeficiency virus test&#xD;
&#xD;
          -  heart, liver, lung or kidney important condition&#xD;
&#xD;
          -  drug or alcohol dependence&#xD;
&#xD;
          -  knowledge or suspicion of malignancy&#xD;
&#xD;
          -  body mass index &lt; 18&#xD;
&#xD;
          -  body mass index &gt; 30&#xD;
&#xD;
          -  participation on any experimental study 12 months prior this study&#xD;
&#xD;
          -  familiar history of colon carcinoma or inflammatory disease&#xD;
&#xD;
          -  Lack of adherence to the procedures of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria EA Moraes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Ceara - UNIFAC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departamento de Fisiologia e Farmacologia</name>
      <address>
        <city>Cear√°</city>
        <state>Fortaleza</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

